Effects of Ondansetron and Granisetron on Postoperative Nausea and Vomiting in Adult Patients Undergoing Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Beştaş, Azize; Önal, Selami Ateş; Bayar, Mustafa Kemal; Yıldırım, Aslı; Aygen, Erhan

doi:10.1016/j.curtheres.2007.10.003

Cited by 13 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Postoperative assessment of nausea, retching, and vomiting at 0-2, 3, 6, 12, and 24-hour intervals in both ondansetron and granisetron groups was found to be statistically insignificant ( P >0.05). This finding is comparable to the study by Bestas et al 22 , who compared the effects of ondansetron and granisetron on PONV in adult patients undergoing laparoscopic cholecystectomy and observed no significant differences in PONV between the active treatment groups.…”

Section: Discussionsupporting

confidence: 88%

“…In our study, the drugs were administered two minutes before the induction of anesthesia based on previous studies by Honkavaara 5 and Bhattacharya and Banerjee 2 . Ondansetron and granisetron reached a peak plasma concentration within 30 minutes of intravenous administration 22 . Hence intravenous administration just before induction provides a sufficient postoperative antiemetic effect.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Comparison of ondansetron and granisetron for antiemetic prophylaxis in maxillofacial surgery patients receiving general anesthesia: a prospective, randomised, and double blind study

Savant¹,

Khandeparker²,

Berwal

et al. 2016

J Korean Assoc Oral Maxillofac Surg

View full text Add to dashboard Cite

ObjectivesTo compare the efficacy of intravenous ondansetron (4 mg, 2 mL) and granisetron (2 mg, 2 mL) for preventing postoperative nausea and vomiting (PONV) in patients during oral and maxillofacial surgical procedures under general anesthesia.Materials and MethodsA prospective, randomized, and double blind clinical study was carried out with 60 patients undergoing oral and maxillofacial surgical procedures under general anesthesia. Patients were divided into two groups of 30 individuals each. Approximately two minutes before induction of general anesthesia, each patient received either 4 mg (2 mL) ondansetron or 2 mg (2 mL) granisetron intravenously in a double blind manner. Balanced anesthetic technique was used for all patients. Patients were assessed for episodes of nausea, retching, vomiting, and the need for rescue antiemetic at intervals of 0-2, 3, 6, 12, and 24 hours after surgery. Incidence of complete response and adverse effects were assessed at 24 hours postoperatively. Data was tabulated and subjected to statistical analysis using the chi-square test, unpaired t-test, or the Mann-Whitney U-test as appropriate. A P-value less than 0.05 was considered statistically significant.ResultsThere was no statistically significant difference between the two groups for incidence of PONV or the need for rescue antiemetic. Both study drugs were well tolerated with minimum adverse effects; the most common adverse effect was headache. The overall incidence of complete response in the granisetron group (86.7%) was significantly higher than the ondansetron group (60.0%).ConclusionGranisetron at an intravenous dose of 2 mg was found to be safe, well tolerated, and more effective by increasing the incidence of complete response compared to 4 mg intravenous ondansetron when used for antiemetic prophylaxis in maxillofacial surgery patients receiving general anesthesia. Benefits of granisetron include high receptor specificity and high potency, which make it a valuable alternative to ondansetron.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Discussionmentioning

confidence: 98%

Comparison of ondansetron and granisetron for antiemetic prophylaxis in maxillofacial surgery patients receiving general anesthesia: a prospective, randomised, and double blind study

Savant¹,

Khandeparker²,

Berwal

et al. 2016

J Korean Assoc Oral Maxillofac Surg

View full text Add to dashboard Cite

show abstract

“…The overall incidence of emesis in 0 -24 hours was similar in both the groups (6.6% in both Group A and Group B), p value > 0.05. Our findings were comparable to the studies by Gigilo 16 and Bestas et al 17 Gigilo in their study to prevent postoperative nausea and vomiting following cancer chemotherapy concluded that both Ondansetron and Granisetron have similar antiemetic efficacy. 16 Bestas et al compared the effects of Ondansetron and Granisetron on PONV in adult patients undergoing laparoscopic cholecystectomy and observed no significant differences in PONV between both the groups.…”

Section: Discussionsupporting

confidence: 91%

“…16 Bestas et al compared the effects of Ondansetron and Granisetron on PONV in adult patients undergoing laparoscopic cholecystectomy and observed no significant differences in PONV between both the groups. 17 In the present study, complete response was found to be 93.3% in both the groups which was comparable to the study by Bhattacharya and Banerjee P 18 when they compared the efficacy of intravenous Granisetron and Ondansetron in preventing post-operative nausea and vomiting in laparoscopic gynaecological surgeries. (Complete response 80% in Ondansetron group and 93% in Granisetron group).…”

Section: Discussionsupporting

confidence: 89%

A Comparative Study of Ondansetron Versus Granisetron in the Prevention of Postoperative Nausea and Vomiting (Ponv) in Day Care Gynaecological Laparoscopic Surgeries

Chakravarthy¹,

Shankar²

2018

jemds

View full text Add to dashboard Cite

BACKGROUND The antiemetic action of 5-hydroxytryptamine receptor antagonists (5HT3 receptor blockers) has been well established. The present study compared the efficacy of the 5HT3 receptor blockers Ondansetron and Granisetron, in reducing the Post-Operative Nausea and Vomiting in day care gynaecological laparoscopic surgeries. Aims and Objectives-To compare the efficacy of intravenous Ondansetron versus Granisetron in the prevention of post-operative nausea and vomiting in patients undergoing day care gynaecological laparoscopic surgeries. MATERIALS AND METHODS 60 patients of ASA Grade 1 and II, between 18-55 years of age undergoing day care gynaecological surgeries were included in the present study. They were allocated into 2 groups of 30 each. The sample size was taken for convenience during the study. Group A received 4 mg (2 mL) of Ondansetron intravenously, Group B received 2 mg (2 mL) of Granisetron intravenously prior to induction of general anaesthesia. Each of these groups were assessed for the incidence of post-operative nausea, pain, emesis and adverse effects. RESULTS Incidence of nausea in the first 2 hrs. was the same in both the groups 16.6% (n= 5). The overall incidence of nausea in 0 to 24 hrs. in Group A and Group B was 23.3% (n= 7) and 20% (n= 6) respectively. The overall incidence of emesis in 0-24 hrs. after the surgery was found to be similar 6.6% (n= 2) in both the groups. No adverse effects were observed in both the groups. There was no statistically significant difference between Ondansetron and Granisetron with regards to their efficacy in minimising postoperative nausea and vomiting (p value > 0.05). CONCLUSION In conclusion, intravenous administration of 4 mg Ondansetron or 2 mg Granisetron prior to induction of general anaesthesia is equally effective in preventing the post-operative nausea and vomiting in day care gynaecological laparoscopic surgeries.

show abstract

“…Granisetron is a potent and highly selective serotonin receptor (5‐hydroxytryptamine‐3 selective) antagonist that is indicated for prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy (label approved by the US Food and Drug Administration). Extensive clinical trials have shown granisetron to be an effective and well‐tolerated agent for the treatment of nausea and vomiting in patients on chemotherapy (Gurpide et al ., ; Ikeda et al ., ; Tsuji et al ., ; Yonemura et al ., ) or in postoperative patients (Aleyasin et al ., ; Bestas et al ., ; Dua et al ., ; Janicki et al ., ). Additionally, it has been reported that the major metabolite of granisetron in human, 7‐hydroxy granisetron (Bloomer et al ., ; Clarke et al ., ), may also have 5‐hydroxytryptamine‐3 receptor antagonist activity (Boppana ; Boppana et al ., ).…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a sensitive liquid chromatographic–tandem mass spectrometric method for the simultaneous analysis of granisetron and 7‐hydroxy granisetron in human plasma and urine samples: application in a clinical pharmacokinetic study in pregnant subject

Zhao

Chen

Caritis

et al. 2015

Biomedical Chromatography

View full text Add to dashboard Cite

A liquid chromatography-tandem mass spectrometric method for the quantification of granisetron and its major metabolite, 7-hydroxy granisetron in human plasma and urine samples was developed and validated. Respective stable isotopically labeled granisetron and 7-hydroxy granisetron were used as internal standards (IS). Chromatography was performed using an Xselect HSS T3 analytical column with a mobile phase of 20% acetonitrile in water (containing 0.2 mM ammonium formate and 0.14% formic acid, pH 4) delivered in an isocratic mode. Tandem mass spectrometry operating in positive electrospray ionization mode with multiple reaction monitoring was used for quantification. The standard curves were linear in the concentration ranges of 0.5-100 ng/mL for granisetron and 0.1-100 ng/mL for 7-hydroxy granisetron in human plasma samples, and 2-2000 ng/mL for granisetron and 2-1000 ng/mL for 7-hydroxy granisetron in human urine samples, respectively. The accuracies were >85% and the precision as determined by the coefficient of variations was <10%. No significant matrix effects were observed for granisetron or 7-hydroxy granisetron in either plasma or urine samples. Granisetron was stable under various storage and experimental conditions. This validated method was successfully applied to a pharmacokinetic study after intravenous administration of 1 mg granisetron to a pregnant subject.

show abstract

Effects of Ondansetron and Granisetron on Postoperative Nausea and Vomiting in Adult Patients Undergoing Laparoscopic Cholecystectomy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Cited by 13 publications

References 17 publications

Comparison of ondansetron and granisetron for antiemetic prophylaxis in maxillofacial surgery patients receiving general anesthesia: a prospective, randomised, and double blind study

Comparison of ondansetron and granisetron for antiemetic prophylaxis in maxillofacial surgery patients receiving general anesthesia: a prospective, randomised, and double blind study

A Comparative Study of Ondansetron Versus Granisetron in the Prevention of Postoperative Nausea and Vomiting (Ponv) in Day Care Gynaecological Laparoscopic Surgeries

Development and validation of a sensitive liquid chromatographic–tandem mass spectrometric method for the simultaneous analysis of granisetron and 7‐hydroxy granisetron in human plasma and urine samples: application in a clinical pharmacokinetic study in pregnant subject

Contact Info

Product

Resources

About